Log In
BCIQ
Print this Print this
 

CG026806

  Manage Alerts
Collapse Summary General Information
Company CrystalGenomics Inc.
DescriptionSmall molecule inhibitor of Bruton's tyrosine kinase (Btk), FMS-like tyrosine kinase 3 (FLT3; CD135) and Aurora kinases
Molecular Target Bruton's tyrosine kinase (Btk) ; FMS-like tyrosine kinase 3 (FLT3) (CD135)
Mechanism of ActionFMS-like tyrosine kinase 3 (FLT3) inhibitor; Aurora kinase inhibitor; Bruton's tyrosine kinase (Btk) inhibitor
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPreclinical
Standard Indication Cancer (unspecified)
Indication DetailsTreat cancer
Regulatory Designation
PartnerAptose Biosciences Inc.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$303.0M

$1.0M

$300.0M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

06/08/2016

$303.0M

$1.0M

$300.0M

Get a free BioCentury trial today